Why carry out this study?

Physiological differences between regional populations have been shown to influence the efficacy and safety of COPD therapies.

The IMPACT trial demonstrated that single-inhaler triple therapy was more efficacious than dual therapy in patients with COPD.

This analysis evaluated differences in efficacy, mortality, and pneumonia risk between Asia and non-Asia regions.

What was learned from the study?

This analysis demonstrated that FF/UMEC/VI provides similar benefits in COPD patients in Asia and non-Asia regions.

Clinical benefits of treatment, including reduction in mortality risk, should be weighed against risk of pneumonia, taking account of all known risk factors.